Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.
Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Arctic Therapeutics announced this week that it has raised €26.5 million, a sum bankrolled by investors including the European Innovation Council (EIC) Fund, the Icelandic investment firm Kaldbakur ...
From Novo Holding’s purchase of Catalent to BMS’s Karuna acquisition, here are 10 of the most significant M&A moments last year Compared to the previous years, 2024 has been a relatively slow year for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback